425: Runway Growth to Acquire SWK Holdings, Boosts Healthcare

Runway Growth Finance Corp. announced a definitive merger agreement to acquire SWK Holdings Corporation, expanding its healthcare and life sciences portfolio and enhancing its financial profile.

Summary

• Runway Growth Finance Corp. (RWAY) has entered into a definitive merger agreement to acquire SWK Holdings Corporation (SWK), a life science focused specialty finance company.
• The acquisition is expected to significantly expand Runway Growth's exposure to the healthcare and life sciences sectors, increasing healthcare investments from 14% to approximately 31% of the portfolio as of June 30, 2025, on a pro forma basis.
• The transaction will expand Runway Growth's total assets to $1.3 billion pro forma for the acquisition, enhancing portfolio scale and diversification.
• The acquisition is anticipated to be accretive to net investment income (NII) by a mid-single-digit run-rate during the first full quarter following the transaction close.
• The estimated purchase price is approximately $220 million, based on SWK's June 30, 2025, financials, comprising $75.5 million in Runway Growth shares and approximately $145 million in cash.
• Runway Growth Capital LLC, the external investment adviser, will contribute an additional $9 million in cash for distribution to SWK stockholders.
• SWK's portfolio includes 22 companies with an approximate fair value of $242 million as of August 15, 2025.
• The transaction is expected to close in late 2025 or the first quarter of 2026, subject to SWK shareholder and regulatory approvals.

Sentiment

Score: 9

Explanation: The filing announces a strategic acquisition that is highly positive for Runway Growth, promising significant NII accretion, substantial portfolio diversification into a key growth sector (healthcare/life sciences), increased scale, and improved financial metrics. The support from BC Partners Credit platform further strengthens the outlook for future growth.

Positives

• Expands investment capabilities and market position in the large and growing healthcare and life sciences sector.
• Increases healthcare investments to approximately 31% of the portfolio from 14% as of June 30, 2025, on a pro forma basis.
• Drives portfolio scale, expanding total assets to $1.3 billion pro forma for the acquisition.
• Enhances portfolio metrics through high-quality investments and a meaningful reduction in average loan size.
• Expected to generate mid-single-digit run-rate NII accretion during the first full quarter post-close.
• Anticipated to improve dividend coverage and Return on Equity (ROE).
• Expands Runway Growth's pro-forma leverage ratio and increases nominal leverage capacity.
• Broadens the shareholder base and increases trading liquidity of common shares through the issuance of $75.5 million in Runway Growth shares.
• Positions Runway Growth for future organic and inorganic growth strategies, supported by the $10 billion BC Partners Credit platform.

Risks

• Uncertainty regarding the ability of the parties to consummate the merger on the expected timeline, or at all.
• Risks associated with realizing the expected synergies and savings from the merger.
• Potential inability to realize the anticipated benefits of the merger, including the elimination of certain expenses and costs.
• Impact of the merger on the depth of trading in Runway's common stock post-closing.
• Possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived.
• Risks related to diverting management's attention from ongoing business operations.
• Uncertainty regarding the combined company's future plans, expectations, objectives, and intentions.
• Potential termination of the merger agreement.
• Uncertainty regarding the future operating results and net investment income projections of the combined company.
• Risks related to the ability of Runway Growth Capital LLC to implement its future plans with respect to the combined company.
• Challenges in attracting and retaining highly talented professionals by Runway Growth Capital LLC and its affiliates.
• Uncertainty regarding the business prospects of the combined company and its portfolio companies.
• Risks associated with expected financings, investments, and additional leverage the combined company may seek to incur.
• Concerns about the adequacy of the cash resources and working capital of the combined company.
• Risk that stockholder litigation in connection with the merger may result in significant costs of defense and liability.
• High degree of risk involved in development programs for medical products, with only a small number resulting in commercialization.

Future Outlook

Runway Growth anticipates that the acquisition will enhance its earnings power, more than offsetting previously signaled loan repayments, and expects to deliver mid-single-digit NII accretion. The company plans to pursue both organic and inorganic growth strategies as a permanent capital vehicle backed by the BC Partners Credit platform, aiming to generate long-term shareholder value through disciplined growth and venture debt investing. The acquisition is expected to improve dividend coverage, ROE, and expand the pro-forma leverage ratio, supporting continued risk-adjusted returns.

Management Comments

• David Spreng, Founder and CEO of Runway Growth, stated, "This transaction meaningfully advances our strategy to diversify and optimize our portfolio by adding SWKs high-quality investments in the key sectors of healthcare and life sciences."
• Spreng also noted, "At the same time, we are enhancing our earnings power, more than offsetting the anticipated loan repayments we previously signaled, and we expect to deliver mid-single-digit NII accretion."
• He emphasized, "This transaction reinforces the strength of Runway Growths portfolio as we work to generate long-term value for our shareholders through disciplined growth and venture debt investing with a focus on excellent credit quality in the sectors we know best."
• Spreng further commented on future plans, "Looking ahead, and with the full support of BC Partners Advisors L.P., we are pursuing growth through both organic and inorganic strategies as a permanent capital vehicle backed by the $10 billion BC Partners Credit platform."
• Spreng concluded, "We are doing all of this while growing our shareholder base, improving our existing robust portfolio metrics and increasing our total assets to $1.3 billion pro forma with the SWK merger transaction."

Industry Context

This acquisition positions Runway Growth to significantly expand its presence in the healthcare and life sciences specialty finance market, a large and growing sector. SWK's focus on minimally dilutive financing for commercial-stage healthcare companies complements Runway Growth's existing strategy of providing flexible capital solutions to lateand growth-stage companies. The move aligns with a broader industry trend of consolidation and specialization within the venture debt and specialty finance space, allowing the combined entity to leverage increased scale and diversified expertise to capture more market share and enhance its competitive advantage.

Corporate Governance

Legal Proceedings

• A risk of stockholder litigation in connection with the merger is identified, which may result in significant costs of defense and liability.

Related Party Transactions

• Runway Growth Capital LLC, in its capacity as Runway Growth's external investment adviser and an affiliate of BC Partners Advisors L.P., will contribute $9 million in cash for distribution as consideration to the stockholders of SWK, separate from the primary merger consideration.

Stakeholder Impact

• Shareholders of Runway Growth are expected to benefit from mid-single-digit NII accretion, improved dividend coverage, enhanced ROE, expanded leverage capacity, and increased trading liquidity of common shares.
• Shareholders of SWK will receive consideration comprising Runway Growth shares and cash, providing liquidity and continued exposure to the combined entity.
• Employees of SWK, particularly those in healthcare and life sciences teams, will be integrated into Runway Growth Capital's investment and deal sourcing teams, suggesting continuity and expanded opportunities.
• The BC Partners Credit platform, as an affiliate of Runway Growth's external manager, will continue to enable and collaborate on both organic and inorganic strategies, reinforcing its strategic partnership.

Next Steps

• SWK shareholder approval of the merger agreement.
• Regulatory approvals for the transaction.
• Fulfillment of other customary closing conditions.
• Runway Growth will hold a conference call on October 10, 2025, to discuss the transaction.
• Runway will file a Combined Proxy Statement and Prospectus with the SEC, containing important information about Runway, SWK, and the proposals.

Key Dates

Recommendation

The acquisition of SWK Holdings is a highly strategic and financially accretive move for Runway Growth. It significantly diversifies the portfolio into the high-growth healthcare and life sciences sectors, expands total assets to $1.3 billion, and is expected to deliver mid-single-digit NII accretion, improving dividend coverage and ROE. The transaction is supported by BC Partners Credit, indicating strong backing for future growth. These factors collectively point to a substantial positive impact on Runway Growth's long-term value and financial performance, making it a strong buy for seasoned investors.

Keywords

Runway Growth Finance Corp, SWK Holdings Corporation, Merger, Acquisition, Healthcare, Life Sciences, Venture Debt, Specialty Finance, BDC, NII Accretion, Portfolio Diversification, BC Partners